Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT01262365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
Study identification
- NCT ID
- NCT01262365
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 793 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- May 2015 (Actual)
- Last update posted
- Sep 28, 2018
2010 – 2015
United States locations
- U.S. sites
- 50
- U.S. states
- 21
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 069 | Birmingham | Alabama | — | — |
| 063 | Little Rock | Arkansas | — | — |
| 085 | Escondido | California | — | — |
| 031 | Los Angeles | California | — | — |
| 051 | Los Angeles | California | — | — |
| 089 | Los Angeles | California | — | — |
| 074 | San Diego | California | — | — |
| 80 | San Gabriel | California | — | — |
| 048 | Aurora | Colorado | — | — |
| 037 | Colorado Springs | Colorado | — | — |
| 039 | Farmington | Connecticut | — | — |
| 042 | Aventura | Florida | — | — |
| 090 | Clearwater | Florida | — | — |
| 092 | DeBary | Florida | — | — |
| 064 | Jupiter | Florida | — | — |
| 082 | Miami | Florida | — | — |
| 070 | Ormond Beach | Florida | — | — |
| 084 | Palm Harbor | Florida | — | — |
| 062 | Tamarac | Florida | — | — |
| 050 | Tampa | Florida | — | — |
| 087 | Vero Beach | Florida | — | — |
| 044 | Lawrenceville | Georgia | — | — |
| 052 | Chicago | Illinois | — | — |
| 096 | Indianapolis | Indiana | — | — |
| 060 | Shreveport | Louisiana | — | — |
| 040 | Baltimore | Maryland | — | — |
| 047 | Saint Clair Shores | Michigan | — | — |
| 067 | Las Cruces | New Mexico | — | — |
| 053 | New York | New York | — | — |
| 077 | Charlotte | North Carolina | — | — |
| 058 | Durham | North Carolina | — | — |
| 061 | Columbus | Ohio | — | — |
| 071 | Middleburg Heights | Ohio | — | — |
| 041 | Oklahoma City | Oklahoma | — | — |
| 076 | Oklahoma City | Oklahoma | — | — |
| 097 | Oklahoma City | Oklahoma | — | — |
| 032 | Duncansville | Pennsylvania | — | — |
| 093 | Philadelphia | Pennsylvania | — | — |
| 073 | Pittsburgh | Pennsylvania | — | — |
| 094 | Pittsburgh | Pennsylvania | — | — |
| 099 | Charleston | South Carolina | — | — |
| 001 | Columbia | South Carolina | — | — |
| 034 | Simpsonville | South Carolina | — | — |
| 057 | Memphis | Tennessee | — | — |
| 078 | Austin | Texas | — | — |
| 098 | Austin | Texas | — | — |
| 079 | Dallas | Texas | — | — |
| 055 | Houston | Texas | — | — |
| 036 | Mesquite | Texas | — | — |
| 066 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01262365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2018 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01262365 live on ClinicalTrials.gov.